Comparative Study of Neuroprotective Activity of Mucuna pruriens and Withania somnifera Against Dopamine inhibitor, Induced Progressive Model for Parkinson’s Disease
Abstract
D:\PROJECT WORK\RESEARCH PAPER FOR JOURNAL PUBLICATION\Research Paper Mary.docx
Keywords:
Biochemical, Behavioural assay, Mucuna pruriens seeds, MTT Assay, Neuroprotective, and Withania somniferaDOI
https://doi.org/10.25004/References
World Health Organization. Parkinson disease. Geneva: World Health Organization; 2023 [cited 2025 Jul 7]. Available from: https://www.who.int/news-room/fact-sheets/detail/parkinson-disease
World Health Organization. Parkinson disease: a public health approach. Geneva: World Health Organization; 2022 [cited 2025 Jul 7]. Available from: https://www.who.int/publications/i/item/9789240044286
National Institute of Neurological Disorders and Stroke. Parkinson’s disease: challenges, progress, and promise [Internet]. Bethesda (MD): National Institutes of Health; 2025 Feb 25 [cited 2025 Jul 7]. Available from: https://www.ninds.nih.gov/current-research/focus-disorders/parkinsons-disease-research
Vaidya DB, Vaidya AB. Traditional plant-based therapies for Parkinson’s disease: a review. J Ayurveda Integr Med. 2021;12(1):135–44. Available from: doi:10.1016/j.jaim.2019.08.005
Reeta KH, Mehla J, Gupta YK. Curcumin and its neuroprotective role in neurological disorders. Neurosci Bull. 2014;30(1):112–23. doi:10.1007/s12264-013-1370-x
Manyam BV. Paralysis agitans and levodopa in Ayurveda: ancient Indian medical knowledge. Mov Disord. 1990;5(1):47–8. Available from: doi:10.1002/mds.870050111
Kumar H, Lim HW, More SV, et al. The role of free radicals in the aging brain and Parkinson’s disease: convergence and parallelism. Int J Mol Sci. 2012;13(8):10478–504. Available from: doi:10.3390/ijms130810478
Kulkarni SK, Dhir A. Bacopa monniera, a nootropic drug, modulates the antioxidant and neuroprotective activity in the brain. Phytother Res. 2008;22(6):749–54. doi:10.1002/ptr.2364
Singh S, Dubey R, Sharma B. Role of natural antioxidants in the management of neurodegenerative disorders: a review. Eur J Med Chem. 2020;176:116113. Available from: doi:10.1016/j.ejmech.2019.116113
Misra A, Ghosh S, Dey CS. Mucuna pruriens improves Parkinsonian symptoms with better tolerability than L-DOPA in MPTP mouse model. Phytother Res. 2013;27(11):1692–8. Available from: doi:10.1002/ptr.4892
Manyam BV, Dhanasekaran M, Hare TA. Neuroprotective effects of the antiparkinson drug Mucuna pruriens. Phytother Res. 2004;18(9):706–12. Available from: doi:10.1002/ptr.1521
Tanner CM. Epidemiology of Parkinson’s Disease. Neurol Clin. 1992;10(2):317–29.
Evans DA, Funkenstein MS, Albert MS, Scherr PA, Cook NR, Chown MJ, et al. Prevalence of Alzheimer’s disease in a community population of older persons. JAMA. 1989;262(18):2251–6.
Kurtzke JF. Epidemiology of Amyotrophic Lateral Sclerosis. In: Rowland LP, editor. Human Motor Neuron Diseases. Adv Neurol. 1982;36:281–302.
Jha DK, Koneri R, Samaddar S. Antidiabetic activity of phytosaponin in STZ-induced type I diabetes in rats. Res J Pharm Technol. 2019;12(8):3919–26. Available from: doi:10.5958/0974-360X.2019.00675.9. Available from: https://rjptonline.org/AbstractView.aspx?PID=2019-12-8-65
Terry AV Jr, Gearhart DA, Warner SE, Zhang G, Bartlett MG, Middlemore ML, et al. Oral haloperidol or risperidone treatment in rats: temporal effects on nerve growth factor receptors, cholinergic neurons, and memory performance. Neuroscience. 2007;146(4):1316–32. Available from: doi:10.1016/j.neuroscience.2007.02.040
Bredberg E, Lennernäs H, Paalzow L. Pharmacokinetics of levodopa and carbidopa in rats following different routes of administration. Pharm Res. 1994;11(4):549–55.
Manna S, Bhattacharyya D, Mandal TK, Dey S. Neuropharmacological effects of deltamethrin in rats. J Vet Sci. 2006;7(2):133–6.
Hu M, Li F, Wang W. Vitexin protects dopaminergic neurons in MPTP-induced Parkinson’s disease through PI3K/Akt signaling pathway. Drug Des Devel Ther. 2018;12:565–73.
Rai SN, Yadav SK, Singh D, Singh SP. Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model. J Chem Neuroanat. 2016;71:41–9.
Jollow DJ, Mitchell JR, Zampaglione NA, Gillette JR. Bromobenzene-induced liver necrosis. Pharmacology. 1974;11(3):151–69.
Ohkawa H, Ohishi N, Yagi K. Reaction of linoleic acid hydroperoxide with thiobarbituric acid. J Lipid Res. 1978;19(8):1053–7.
Farombi EO, Awogbindin IO, Farombi TH, Oladele JO, Izomoh ER, Aladelokun OB, et al. Neuroprotective role of kolaviron in striatal redo-inflammation associated with rotenone model of Parkinson’s disease. Neurotoxicology. 2019;73:132–41.
Mir UF, Jha DK, Chatterjee S. Pro inflammatory cytokines predict the response of cancer treatment. Indian J Pharm Educ Res. 2025;59(2):441–52. Available from: doi:10.5530/ijper.20254089
Dulal TR, Jha DK, Sah SK, Fathima M. Evaluation of the antipsychotic and neuroprotective properties of Bergenia ciliata root extract in rat models. Int J Pharm Sci Drug Res. 2024;16(6):1023–31. Available from: doi:10.25004/IJPSDR.2024.160613
Ashhar MU, Kumar S, Ali J, Baboota S. CCRD based development of bromocriptine and glutathione nanoemulsion tailored ultrasonically for the combined anti-parkinson effect. Chem Phys Lipids. 2021;235:105035. Available from: doi:10.1016/j.chemphyslip.2020.105035
Blesa J, Phani S, Jackson-Lewis V, Przedborski S. Classic and new animal models of Parkinson’s disease. J Biomed Biotechnol. 2012;2012:1–10.
Vargas D, Ober AG, Fischer NH. Sesquiterpene lactones from three populations of Calea urticifolia. Rev Latinoam Quim. 1989;20:11.
Voon V, Napier TC, Frank MJ, Sgambato-Faure V, Grace AA, Rodriguez-Oroz M, et al. Impulse control disorders and levodopa-induced dyskinesia in Parkinson’s disease: an update. Lancet Neurol. 2017;16(3):238–50.
Tripathi YB, Upadhyay AK. Antioxidant property of Mucuna pruriens Linn. Curr Sci. 2001;80:1377–8.
Spencer JPE, Jenner A, Butler J, Aruoma OI, Dexter DT, Jenner P, et al. Evaluation of the pro-oxidant and anti-oxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson’s disease. Free Radic Res. 1996;24(2):95–105.
Spencer JPE, Jenner P, Halliwell B. Superoxide-dependent depletion of reduced glutathione (GSH) by L-DOPA and dopamine: relevance to Parkinson’s disease. Neuroreport. 1995;6(11):1480–4.
Majolo F, Rehfeldt S, Henriques JAP, Contini V, Goettert MI. Approaches for the treatment of neurodegenerative diseases related to natural products. Stud Nat Prod Chem. 2021;69:1–63.
Published
Abstract Display: 9 How to Cite
Issue
Section
Copyright (c) 2025 Mary Brenda Ogwang, Dr. Deepak Kumar Jha
This work is licensed under a Creative Commons Attribution 4.0 International License.
